SCS CEO Appointed to Board

Stem Cell Sciences plc
21 November 2007



Press Release

     STEM CELL SCIENCES APPOINTS DR ALASTAIR RIDDELL AS EXECUTIVE DIRECTOR

21 November 2007

Stem Cell Sciences plc (SCS, AIM:STEM, ASX: STC) the global biotechnology
company focused on the commercialisation of stem cells and stem cell
technologies in research and cell-based therapies, announces today that Dr
Alastair James Riddell (58), CEO of SCS, has been appointed as an Executive
Director with immediate effect.

Dr Riddell is currently a Non-Executive Director of Sareum Holdings plc, a
specialist structure-based drug discovery company, and is an active Board member
of the BioIndustry Association, a position he has held from 2000 to 2006 and
recently re-elected to serve for the 2008 term. He was previously Non-Executive
Chairman of Surface Therapeutics Limited overseeing the company's acquisition by
Serentis Inc. in September 2007. Dr Riddell was formerly a director at Paradigm
Therapeutics Limited, Pharmagene plc, Pharmagene Laboratories Trustees Limited
and Pharmagene Therapeutics Limited.

The Company confirms there is no other information required to be disclosed
under Schedule 2 paragraph (g) of the AIM Rules.


                                    - Ends -

For further information, please contact:

Stem Cell Sciences plc (United Kingdom)                          [phone]
Alastair Riddell, CEO

Halsin Partners (United Kingdom)                                 [phone]
Michael Sinclair, Director

Talk Biotech (Australia)                                         [phone]
Fay Weston

Stem Cell Sciences llc (USA)                                     [phone]
David Dodd, Chairman of SCS plc

Notes to Editors

About Stem Cell Sciences plc

Stem Cell Sciences plc (SCS, AIM: STEM) is a global biotechnology company,
established in Melbourne, Australia in 1994, providing products in the
burgeoning stem cell research and drug discovery markets, in addition to the
targeted development of cell-based therapies for neurodegenerative disease and
injury.

The Company has established a leading intellectual property (IP) and technology
portfolio that enables the commercial application of stem cells in drug
discovery, providing the Company with early-stage revenue streams and technology
development for at scale cell production of SCS cell-based therapeutics. SCS
principal focus is in neurological disease. Revenues in the neurotech market,
including pharmaceuticals, devices and diagnostics, grew 10% in 2005 to US$110
billion Neurotech Insights, Volume 2/3 April 30 2006.

SCS has operations in the UK, US and Australia, and is affiliated with academic
centres of excellence, including the Institute of Stem Cell Research (ISCR),
Edinburgh, UK, RIKEN Centre for Development Biology, Kobe, Japan and the
Australian Stem Cell Centre, Melbourne, Australia.

For further information on the company please visit: www.stemcellsciences.com


                      This information is provided by RNS
            The company news service from the London Stock Exchange